Drug Trial Radar · NCT01257074
Non-inferiority Comparison of Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes Labialis
Last checked: Nov 20, 2026Latest source record: Mar 4, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
76
Actual
Start
Feb 2012
Primary completion
Mar 2012
Study completion Oct 2012
Sponsor
- Lead sponsor
- EMSIndustry
- Sponsor type
- Industry
- First posted
- Dec 9, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Herpes labialis is the most common recurrent manifestation of herpes simplex. The purpose of this study is to check the non-inferiority efficacy and safety of penciclovir 10mg/g as treatment for Herpes Labialis in comparison to acyclovir 50mg/g.
Conditions
- Herpes Labialis
Interventions
Acyclovir 50mg/gDrug
Cream, dose 5 times daily during 5 days
Penciclovir 10mg/gDrug
Cream, dose 5 times daily during 5 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy will be evaluated by the proportion of subjects with non herpes labialis manifestationTime frame: Day 10
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Flavia Addor
São Paulo, São Paulo, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.